September 04, 2013
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Imprimis Pharma acquires rights to new ophthalmic surgery drug
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Imprimis Pharmaceuticals Inc. has acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents, according to a company press release.
The company believes this formulation has the potential to significantly impact cataract surgery, according to the release.
The target compound, referred to as IPI-140, is based on a novel combination of moxifloxacin and triamcinolone, the release said.
When placed as a depot inside the vitreous concurrent with cataract surgery, or any intraocular procedure, the compound addresses infection risk and postoperative inflammation, according to the release.